论文部分内容阅读
目的:评价阿奇霉素治疗小儿支原体肺炎的临床效果。方法:选取2015年3月-2016年3月我院收治的96例小儿支原体肺炎患者作为观察对象,随机分为对照组和观察组,各48例;对照组患者给予常规治疗方法,观察组患者在常规治疗的基础上重点采取阿奇霉素治疗,对比两组患者临床治疗效果,并统计两组患者的不良反应发生情况。结果:在治疗总有效率上,观察组为95.83%,明显要比对照组的66.67%高,两组数据差异有统计学意义(P<0.05)。在不良反应发生率上,观察组为4.17%,对照组为6.25%,两组比较无明显差异(P>0.05)。结论:阿奇霉素治疗小儿支原体肺炎患儿效果显著,且不良反应发生率低;因此,值得在临床治疗中推广及使用。
Objective: To evaluate the clinical effect of azithromycin in treating children with mycoplasma pneumonia. Methods: A total of 96 children with mycoplasma pneumonia admitted in our hospital from March 2015 to March 2016 were randomly divided into control group and observation group, with 48 cases in each group. Patients in control group were given routine treatment and patients in observation group In the conventional treatment based on the focus on azithromycin treatment, the clinical efficacy of two groups were compared, and statistics of adverse reactions in both groups of patients. Results: In the total effective rate, the observation group was 95.83%, which was obviously higher than that of the control group (66.67%). There was significant difference between the two groups (P <0.05). The incidence of adverse reactions, the observation group was 4.17%, control group was 6.25%, no significant difference between the two groups (P> 0.05). Conclusion: Azithromycin in children with mycoplasma pneumonia has a significant effect, and the incidence of adverse reactions is low; therefore, it is worth in the clinical treatment to promote and use.